|
1
|
Muscarinic receptor subtypes and smooth muscle function.
|
Pharmacol Rev
|
1996
|
2.55
|
|
2
|
Pulmonary mucormycosis: results of medical and surgical therapy.
|
Ann Thorac Surg
|
1994
|
2.19
|
|
3
|
Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase.
|
Br J Pharmacol
|
1997
|
1.29
|
|
4
|
Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle.
|
Br J Pharmacol
|
1998
|
1.14
|
|
5
|
Pharmacological analyses of endo-6-methoxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-2,3-dihydro-2-oxo-1 H- benzimidazole-1-carboxylate hydrochloride (DAU 6285) at the 5-hydroxytryptamine4 receptor in the tunica muscularis mucosae of rat esophagus and ileum of guinea pig: role of endogenous 5-hydroxytryptamine.
|
J Pharmacol Exp Ther
|
1993
|
1.05
|
|
6
|
Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
|
Br J Pharmacol
|
1995
|
1.04
|
|
7
|
Intestinal tachyarrhythmias during small bowel ischemia.
|
Am J Physiol
|
1999
|
1.00
|
|
8
|
Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.
|
Antimicrob Agents Chemother
|
2012
|
0.98
|
|
9
|
RS 23597-190: a potent and selective 5-HT4 receptor antagonist.
|
Br J Pharmacol
|
1993
|
0.98
|
|
10
|
Comparative pharmacology of recombinant human M3 and M5 muscarinic receptors expressed in CHO-K1 cells.
|
Br J Pharmacol
|
1999
|
0.90
|
|
11
|
Effect of exercise during the follicular and luteal phases on indices of oxidative stress in healthy women.
|
Med Sci Sports Exerc
|
1999
|
0.89
|
|
12
|
Pulsatile versus nonpulsatile reperfusion improves cerebral blood flow after cardiac arrest.
|
Ann Thorac Surg
|
1993
|
0.84
|
|
13
|
The 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat.
|
Pharmacol Res
|
2006
|
0.80
|
|
14
|
RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo.
|
J Pharmacol Exp Ther
|
1993
|
0.80
|
|
15
|
Evaluation of oral ro70-0004/003, an alpha1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction.
|
Int J Impot Res
|
2001
|
0.80
|
|
16
|
Prophylactic implantable defibrillator patches in patients at high risk for malignant ventricular dysrhythmias.
|
ASAIO J
|
1993
|
0.79
|
|
17
|
Cardiovascular dopamine receptors: role of renal dopamine and dopamine receptors in sodium excretion.
|
Pharmacol Toxicol
|
1990
|
0.78
|
|
18
|
Renal dopamine and tubular DA-1 receptors in the regulation of sodium excretion.
|
J Auton Pharmacol
|
1990
|
0.77
|
|
19
|
Crystallization and preliminary x-ray diffraction studies of a Bowman-Birk inhibitor from Vigna unguiculata seeds.
|
Acta Crystallogr D Biol Crystallogr
|
1999
|
0.76
|
|
20
|
In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.
|
J Pharmacol Exp Ther
|
2013
|
0.76
|
|
21
|
Functional characterization of rat submaxillary gland muscarinic receptors using microphysiometry.
|
Br J Pharmacol
|
2001
|
0.75
|
|
22
|
Calcium dependent effects of dimethyl sulphoxide on isolated frog heart and skeletal muscle.
|
Indian J Exp Biol
|
1987
|
0.75
|
|
23
|
Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor.
|
J Cardiovasc Pharmacol
|
1998
|
0.75
|
|
24
|
Cardiovascular pharmacology of adrenergic and dopaminergic receptors: therapeutic significance in congestive heart failure.
|
Am J Med
|
1991
|
0.75
|
|
25
|
Phosphorus-nitrogen compounds. 31. N-phosphinylamino-1,2,5,6-tetrahydropyridines: analgesic activity and effect on blood glucose.
|
Pharm Res
|
1989
|
0.75
|
|
26
|
Intraoperative timing may provide criteria for use of post-cardiotomy ventricular assist devices.
|
ASAIO J
|
1993
|
0.75
|
|
27
|
Sensing lead insulation fractures following implantable cardioverter-defibrillator placement.
|
ASAIO J
|
1994
|
0.75
|
|
28
|
Optimal defibrillator patch configurations include the right side of the heart and left ventricle.
|
Am J Cardiol
|
1993
|
0.75
|